Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?

  title={Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?},
  author={Anne Corbould},
  journal={Diabetes/Metabolism Research and Reviews},
  • A. Corbould
  • Published 1 October 2008
  • Medicine, Biology
  • Diabetes/Metabolism Research and Reviews
Hyperinsulinemia as a consequence of insulin resistance causes hyperandrogenemia in women. [] Key Method An Entrez-PubMed search was conducted to identify studies addressing the relationship of androgens with metabolic syndrome/type 2 diabetes in women. Studies reporting outcomes of androgen administration, interventions to reduce androgen effects in hyperandrogenemic women, and basic studies investigating androgen effects on insulin target tissues were reviewed. Multiple studies showed associations between…

Effects of endogenous androgens and abdominal fat distribution on the interrelationship between insulin and non-insulin-mediated glucose uptake in females.

The decreased IMGU in PCOS is not accompanied by a compensatory increase in NIMGU or associated with excessive VAT accumulation, and increased general obesity, SAT, and hyperandrogenism are primary predictors of the deterioration of NIM GU.

Polycystic Ovary Syndrome. Androgen excess and insulin resistance in women: Identification of molecular targets to improve glucose homeostasis

It is demonstrated that women with PCOS have multiple differentially methylated sites that are associated to gene expression changes in adipose tissue and skeletal muscle, and if electroacupuncture could be used to restore altered CpG sites and transcriptional alterations is investigated.

Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause.

Early postmenopausal PCOS women are characterized by hyperinsulinemia but attenuated insulin resistance, and the differences reported in adipocytokine levels between PCOS and non-PCOS women in reproductive years seem to disappear after menopause.

Androgens in polycystic ovary syndrome: the role of exercise and diet.

It is pointed out that whether in conjunction with pharmacotherapy or as a stand-alone treatment, diet and exercise training represent a fundamental strategy in the treatment of PCOS women.

Androgen effects on adipose tissue architecture and function in nonhuman primates.

Ex vivo studies demonstrate that androgens are essential for normal adipogenesis in males and can impair essential adipocyte functions in females, thus strengthening the experimental basis for sex-specific effects of androgens in adipose tissue.

Interrelationships of serum androgens, omental adipose tissue metabolism, and nonalcoholic fatty liver disease in obese premenopausal women.

Serum testosterone or androstanediol glucuronide (an indicator of peripheral androgen metabolism) were not related to markers of inflammation or lipid metabolism in omental adipose tissue, and primarily correlative data suggest that physiological-range androgen levels do not influence inflammation or cholesterol metabolism in Omental adiposes tissue of women.

Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome

Predictors of Insulin Resistance and Metabolic Complications in Polycystic Ovarian Syndrome in an Eastern Indian Population

Hyperandrogenemia and central obesity were the major factors predicting development of insulin resistance and its related metabolic and cardiovascular complications in PCOS patients, and early monitoring for androgen level and WHR is suggested to minimise future cardiovascular risks.

Childhood obesity and its impact on the development of adolescent PCOS.

Weight loss represents an important therapeutic target in obese adolescents with PCOS because they are at risk for comorbidities such as metabolic syndrome and impaired glucose tolerance, and concomitant obesity compounds these risks.



Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism.

The data suggest that physiological testosterone replacement in women with hypopituitarism for 12 months does not increase, and may improve, insulin resistance, and large, randomized, placebo-controlled studies are needed to determine whether low-dose testosterone replacement affects cardiovascular risk and event rates in women.

Androgen excess in women--a health hazard?

Effect of Two Modes of Antiandrogen Treatment on Insulin Sensitivity and Serum Leptin in Women with PCOS

Leptin levels do not adequately reflect changes in insulin sensitivity or androgen levels after short-term antiandrogen or antigonadotropin treatment, and are correlated only with body weight and body fat.

No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide.

It is demonstrated that the short-term hyperinsulinemia achieved with the clamp technique does not affect androgen secretion and that insulin resistance, measured with the same technique, is not influenced by long-term suppression of plasma androgen levels in polycystic ovary syndrome.

Androgens, insulin resistance and vascular disease in men

Type 2 diabetes mellitus is increasing globally and is an established risk factor for the development of atherosclerotic vascular disease. Insulin resistance is the hallmark feature of type 2

The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.

Antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used, suggesting that in women, androgen excess per se contributes to impairment of insulin action.

Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women.

Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study.

In older women, SHBG is negatively associated with MetS independently of confounders, including inflammatory markers and insulin resistance, and the notion that raising SH BG is a potential therapeutic target for prevention and treatment is supported.

Sex steroids and insulin resistance.

Recognition and treatment of sex steroid-associated insulin resistance at an early stage in patients may reduce their risk of developing Type II (non-insulin-dependent) diabetes mellitus, hypertension and dyslipidaemia, and so may improve fertility and reduce cardiovascular risk.